Neurocrine reports promising phase 2 depression drug data By Investing.com

Published on 23 Apr 2024 on Investing.com

Neurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) announced today that its Phase 2 study for...

Read the rest of the article

Start tracking your investments with Statfolio

Wells Fargo upgrades Neurocrine BioSciences citing its strong pipeline. Read more here.

Seeking Alpha 24 Apr 2024

Neurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) announced today that its Phase 2 study f...

Investing.com 23 Apr 2024

Neurocrine Biosciences (NBIX) stock rises as its Phase 2 trial for depression therapy NBI-1065845...

Seeking Alpha 23 Apr 2024

Investing.com 23 Apr 2024

In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our ...

Insider Monkey via Yahoo Finance 22 Apr 2024

Neurocrine (NASDAQ:NBIX) Biosciences Inc.'s (NASDAQ:NBIX) Chief Commercial Officer, Eric Benevich...

Investing.com 17 Apr 2024

H.C. Wainwright initiated coverage on Voyager Therapeutics Inc VYGR, noting a growing franchise o...

Benzinga 19 Mar 2024

Neurocrine Biosciences Inc (NASDAQ:NBIX), a company specializing in the development of treatments...

GuruFocus.com via Yahoo Finance 16 Mar 2024

In a recent financial move, Ingrid Delaet, the Chief Regulatory Officer of Neurocrine (NASDAQ:NBI...

Investing.com 15 Mar 2024

In a recent transaction, Pops Richard F, a director at Neurocrine (NASDAQ:NBIX) Biosciences Inc...

Investing.com 15 Mar 2024